H1/H1 genotype influences symptom severity in corticobasal syndrome

Movement Disorders

Volumn 25, Issue 6, 2010, Pages 760-763

  Litvan, Irene ^a   Chism, Amanda ^a   Litvan, Juan ^a   Cambon, Alex ^b   Hutton, Michael ^c,d  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c MAYO CLINIC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ApoE; Corticobasal syndrome; H1 H1 genotype

Indexed keywords

APOLIPOPROTEIN E4;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DISEASE SEVERITY; GENOTYPE; HUMAN; INHERITANCE; MATTIS DEMENTIA RATING SCALE; MINI MENTAL STATE EXAMINATION; ONSET AGE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RISK; SURVIVAL RATE; SYMPTOM; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 77951786957     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22804     Document Type: Article

References (10)

1. Boeve BF, Maraganore DM, Parisi JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999;53:795-800.
2. Di Maria E, Tabaton M, Vigo T, et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 2000;47:374-377. (Pubitemid 30141849)
3. Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-1706. (Pubitemid 32574570)
4. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
5. Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005;14:3281-3292. (Pubitemid 41631302)
6. R: A language and environment for statistical computing [program]. Version 2.7. Vienna, Austria: R Foundation for Statistical Computing, 2008.
7. Survival: Survival analysis, including penalized likelihood [program]. Version 2 2008;34-41.
8. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC, 1999.
9. Baba Y, Putzke JD, Tsuboi Y, et al. Effect of MAPT and APOE on prognosis of progressive supranuclear palsy. Neurosci Lett 2006;405:116-119. (Pubitemid 44142824)
10. Litvan I, Baker M, Hutton M. Tau genotype: no effect on onset, symptom severity, or survival in progressive supranuclear palsy. Neurology 2001;57:138-140.